Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3937645 | 0.86 | PARP1 (0.40) | LRRK2PARP1HTTPRMT5WDR77 | |
| SCHEMBL3936795 | 0.84 | ALDH1A1 (0.36) | LRRK2LMNAMAPTHTT | |
| SCHEMBL3944568 | 0.82 | KDM4E (0.32) | LMNA | |
| SCHEMBL3946011 | 0.81 | MAPK1 (0.35) | — | |
| SCHEMBL3941215 | 0.81 | ADORA1 (0.34) | LMNAMAPTTSHR | |
| SCHEMBL3945481 | 0.79 | HTT (0.33) | HTT | |
| SCHEMBL4132211 | 0.78 | ALDH1A1 (0.34) | LRRK2LMNAMAPTHTT | |
| SCHEMBL3947587 | 0.77 | MAPK14 (0.33) | — | |
| SCHEMBL3944968 | 0.77 | PIK3CD (0.30) | — | |
| SCHEMBL3935854 | 0.77 | ALDH1A1 (0.34) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | TEIJIN LIMITED (JP) | 2005-12-15 | — | — | US | disclosed |
| EP-1477489-A1 | PYRROLOPYRIMIDINE DERIVATIVES | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | LRRK2 579/4885PARP1 100/4885LMNA 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.